Restricted Mean Survival Time—Can It Be a New Tool in Assessing the Survival of Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors?

Restricted Mean Survival Time—Can It Be a New Tool in Assessing the Survival of Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors?

Background: Lung cancer (LC) is the first and most lethal cancer in the world; identifying new methods to treat it, such as immune checkpoint inhibitors (ICIs), is needed. ICIs treatment is very effective, but it comes bundled with a series of immune-related adverse events (irAEs). Restricted mean s...

Full description

Bibliographic Details
Main Authors: Cristina-Florina Pîrlog, Raluca Costache, Andreea Ioana Paroșanu, Cristina Orlov Slavu, Mihaela Olaru, Ana Maria Popa, Cristian Iaciu, Irina Niță, Pompilia Moțatu, Horia Teodor Cotan, Alexandru Vlad Oprița, Daniel Costache, Loredana Sabina Cornelia Manolescu, Cornelia Nițipir
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Diagnostics
Subjects:
lung cancer
immune checkpoint inhibitors
immune-related adverse events
restricted mean survival time
Online Access:https://www.mdpi.com/2075-4418/13/11/1892

Internet

https://www.mdpi.com/2075-4418/13/11/1892

Similar Items